TRODELVY (sacituzumab govitecan-hziy)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS · PD-L1 EXPRESSING TRIPLE-NEGATIVE BREAST CANCER ·+2
GILEAD SCIENCES
Drug class
Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib
Antineoplastic TROP2-directed antibody-topoisomerase I inhibitor conjugates are a specialized class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy. Read more about Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib preselected. Add indication or manufacturer filters there.
Antineoplastic TROP2-directed antibody-topoisomerase I inhibitor conjugates are a specialized class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy.
These agents link a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2)—a transmembrane glycoprotein widely overexpressed on various epithelial tumors—to a potent topoisomerase I inhibitor cytotoxic payload (such as SN-38 or deruxtecan derivatives).
Upon binding to TROP2 and undergoing receptor-mediated internalization, the conjugate releases the payload to induce DNA strand breaks, arrest replication, and trigger apoptosis in malignant cells.
Clinically, this drug class, exemplified by agents like sacituzumab govitecan, is primarily utilized in solid tumors, most notably advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and locally advanced or metastatic urothelial carcinoma.
-
nih.gov
Antineoplastic TROP2-directed antibody-topoisomerase I inhibitor conjugates are a specialized class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy These agents link a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2)—a transmembrane glycoprotein widely overexpressed on various epithelial tumors—to a potent topoisomerase I inhibitor cytotoxic payload (such as SN-38 or deruxtecan derivatives) Clinically, this drug class, exemplified by agents like sa...
-
gosset.ai
Antineoplastic TROP2-directed antibody-topoisomerase I inhibitor conjugates are a specialized class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy
-
onclive.com
These agents link a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2)—a transmembrane glycoprotein widely overexpressed on various epithelial tumors—to a potent topoisomerase I inhibitor cytotoxic payload (such as SN-38 or deruxtecan derivatives) Clinically, this drug class, exemplified by agents like sacituzumab govitecan, is primarily utilized in solid tumors, most notably advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breas...
-
medchemexpress.com
Upon binding to TROP2 and undergoing receptor-mediated internalization, the conjugate releases the payload to induce DNA strand breaks, arrest replication, and trigger apoptosis in malignant cells
-
rxlist.com
Upon binding to TROP2 and undergoing receptor-mediated internalization, the conjugate releases the payload to induce DNA strand breaks, arrest replication, and trigger apoptosis in malignant cells
-
biochempeg.com
Clinically, this drug class, exemplified by agents like sacituzumab govitecan, is primarily utilized in solid tumors, most notably advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and locally advanced or metastatic urothelial carcinoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.